180 related articles for article (PubMed ID: 33126538)
21. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
[TBL] [Abstract][Full Text] [Related]
22. Combined Inhibition of Gα
Hitchman TD; Bayshtok G; Ceraudo E; Moore AR; Lee C; Jia R; Wang N; Pachai MR; Shoushtari AN; Francis JH; Guan Y; Chen J; Chang MT; Taylor BS; Sakmar TP; Huber T; Chi P; Chen Y
Clin Cancer Res; 2021 Mar; 27(5):1476-1490. PubMed ID: 33229459
[TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of GNAQ/11 mutation inversely correlates with the metastatic rate in uveal melanoma.
Liang C; Peng LY; Zou M; Chen X; Chen Y; Chen H; Xiao L; Yan N; Zhang J; Zhao Q; Huang X
Br J Ophthalmol; 2021 Apr; 105(4):587-592. PubMed ID: 31533929
[TBL] [Abstract][Full Text] [Related]
24. Targeting GNAQ/11 through PKC inhibition in uveal melanoma.
Lietman CD; McKean M
Cancer Gene Ther; 2022 Dec; 29(12):1809-1813. PubMed ID: 35181742
[TBL] [Abstract][Full Text] [Related]
25. Mutant GNAQ promotes cell viability and migration of uveal melanoma cells through the activation of Notch signaling.
Liu H; Lei C; Long K; Yang X; Zhu Z; Zhang L; Liu J
Oncol Rep; 2015 Jul; 34(1):295-301. PubMed ID: 25955651
[TBL] [Abstract][Full Text] [Related]
26. BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells.
Ambrosini G; Sawle AD; Musi E; Schwartz GK
Oncotarget; 2015 Oct; 6(32):33397-409. PubMed ID: 26397223
[TBL] [Abstract][Full Text] [Related]
27. Prognostic impact of chromosomal aberrations and GNAQ, GNA11 and BAP1 mutations in uveal melanoma.
Staby KM; Gravdal K; Mørk SJ; Heegaard S; Vintermyr OK; Krohn J
Acta Ophthalmol; 2018 Feb; 96(1):31-38. PubMed ID: 28444874
[TBL] [Abstract][Full Text] [Related]
28. Mutations of GNAQ, GNA11, SF3B1, EIF1AX, PLCB4 and CYSLTR in Uveal Melanoma in Chinese Patients.
Hou C; Xiao L; Ren X; Tang F; Guo B; Zeng W; Liang C; Yan N
Ophthalmic Res; 2020; 63(3):358-368. PubMed ID: 31614358
[TBL] [Abstract][Full Text] [Related]
29. Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic GNAQ mutations.
Mudhar HS; Doherty R; Salawu A; Sisley K; Rennie IG
Br J Ophthalmol; 2013 Jul; 97(7):924-8. PubMed ID: 23685997
[TBL] [Abstract][Full Text] [Related]
30. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Falchook GS; Lewis KD; Infante JR; Gordon MS; Vogelzang NJ; DeMarini DJ; Sun P; Moy C; Szabo SA; Roadcap LT; Peddareddigari VG; Lebowitz PF; Le NT; Burris HA; Messersmith WA; O'Dwyer PJ; Kim KB; Flaherty K; Bendell JC; Gonzalez R; Kurzrock R; Fecher LA
Lancet Oncol; 2012 Aug; 13(8):782-9. PubMed ID: 22805292
[TBL] [Abstract][Full Text] [Related]
31. Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.
Gaffal E
J Dtsch Dermatol Ges; 2020 Nov; 18(11):1245-1248. PubMed ID: 32954611
[TBL] [Abstract][Full Text] [Related]
32. Uveal melanoma driver mutations in GNAQ/11 yield numerous changes in melanocyte biology.
Perez DE; Henle AM; Amsterdam A; Hagen HR; Lees JA
Pigment Cell Melanoma Res; 2018 Sep; 31(5):604-613. PubMed ID: 29570931
[TBL] [Abstract][Full Text] [Related]
33. Dual Inhibition of Histone Deacetylases and the Mechanistic Target of Rapamycin Promotes Apoptosis in Cell Line Models of Uveal Melanoma.
Patel RP; Thomas JR; Curt KM; Fitzsimmons CM; Batista PJ; Bates SE; Gottesman MM; Robey RW
Invest Ophthalmol Vis Sci; 2021 Sep; 62(12):16. PubMed ID: 34533562
[TBL] [Abstract][Full Text] [Related]
34. GNAQ and GNA11 mutant nonuveal melanoma: a subtype distinct from both cutaneous and uveal melanoma.
Livingstone E; Zaremba A; Horn S; Ugurel S; Casalini B; Schlaak M; Hassel JC; Herbst R; Utikal JS; Weide B; Gutzmer R; Meier F; Koelsche C; Hadaschik E; Sucker A; Reis H; Merkelbach-Bruse S; Siewert M; Sahm F; von Deimling A; Cosgarea I; Zimmer L; Schadendorf D; Schilling B; Griewank KG
Br J Dermatol; 2020 Nov; 183(5):928-939. PubMed ID: 32064597
[TBL] [Abstract][Full Text] [Related]
35. Oncogenic mutations in GNAQ occur early in uveal melanoma.
Onken MD; Worley LA; Long MD; Duan S; Council ML; Bowcock AM; Harbour JW
Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5230-4. PubMed ID: 18719078
[TBL] [Abstract][Full Text] [Related]
36. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
[TBL] [Abstract][Full Text] [Related]
37. Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma.
Bauer J; Kilic E; Vaarwater J; Bastian BC; Garbe C; de Klein A
Br J Cancer; 2009 Sep; 101(5):813-5. PubMed ID: 19654573
[TBL] [Abstract][Full Text] [Related]
38. The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability.
Li Y; He J; Qiu C; Shang Q; Qian G; Fan X; Ge S; Jia R
J Cell Biochem; 2019 Apr; 120(4):5766-5776. PubMed ID: 30320917
[TBL] [Abstract][Full Text] [Related]
39. Genetic and clinico-pathologic analysis of metastatic uveal melanoma.
Griewank KG; van de Nes J; Schilling B; Moll I; Sucker A; Kakavand H; Haydu LE; Asher M; Zimmer L; Hillen U; Thompson JF; Scolyer RA; Schadendorf D; Murali R
Mod Pathol; 2014 Feb; 27(2):175-83. PubMed ID: 23887304
[TBL] [Abstract][Full Text] [Related]
40. Targeting primary and metastatic uveal melanoma with a G protein inhibitor.
Onken MD; Makepeace CM; Kaltenbronn KM; Choi J; Hernandez-Aya L; Weilbaecher KN; Piggott KD; Rao PK; Yuede CM; Dixon AJ; Osei-Owusu P; Cooper JA; Blumer KJ
J Biol Chem; 2021; 296():100403. PubMed ID: 33577798
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
